Update shared on05 Sep 2025
With both the discount rate and future P/E remaining virtually unchanged, there is no notable shift in valuation drivers, resulting in the consensus analyst price target for Poly Medicure holding steady at ₹2277.
What's in the News
- Poly Medicure incorporated a wholly owned step-down subsidiary, RisoR Holdings B.V., in Amsterdam, Netherlands, to acquire a 90% economic interest in the PendraCare Group via agreements with Welling Holdings B.V.
- Management confirmed strong liquidity (INR 12,490 million), supporting both organic and inorganic growth; active M&A strategy focused on technology acquisitions in core and adjacent medical verticals.
- Board scheduled to consider and approve unaudited financial results for Q1 FY2025 and other matters.
- Extraordinary shareholder meeting called to amend the ESOP scheme, regularize Vishal Baid’s appointment as executive director (with remuneration approval), and appoint a secretarial auditor for FY2025-2030.
Valuation Changes
Summary of Valuation Changes for Poly Medicure
- The Consensus Analyst Price Target remained effectively unchanged, at ₹2277.
- The Discount Rate for Poly Medicure remained effectively unchanged, moving only marginally from 13.86% to 13.83%.
- The Future P/E for Poly Medicure remained effectively unchanged, moving only marginally from 69.76x to 69.71x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.